Topalian, Suzanne L, et al. “Targeting the PD-1 B7-H1(PD-L1) Pathway to Activate Anti-Tumor Immunity”. Current Opinion in Immunology, vol. 24, no. 2, 2012, pp. 207-12, https://doi.org/10.1016/j.coi.2011.12.009.
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2012). Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Current Opinion in Immunology, 24(2), 207-212. https://doi.org/10.1016/j.coi.2011.12.009
Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Current Opinion in Immunology. 2012;24(2):207-12.
The category
Medicine: Medicine (General) 10 is the most frequently represented among the references in this article. It primarily includes studies from Nature Medicine The chart below illustrates the number of referenced publications per year.
The first research to cite this article was titled Immune Escape Mechanisms in Diffuse Large B-Cell Lymphoma and was published in 2012. The most recent citation comes from a 2024 study titled Immune Escape Mechanisms in Diffuse Large B-Cell Lymphoma . This article reached its peak citation in 2015 , with 118 citations.It has been cited in 442 different journals, 23% of which are open access. Among related journals, the Frontiers in Immunology cited this research the most, with 26 citations. The chart below illustrates the annual citation trends for this article.